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Peripheral arterial disease (PAD) affects a signiﬁcant portion of the United States population, and much research has been
conducted on identifying populations at risk for PAD, evaluating appropriate diagnostic modalities for PAD, studying
the effect of risk factor reduction on PAD progression, and determining the best method of treatment for symptomatic
PAD. However, most PAD research and clinical trials have focused on whole populations, or populations consisting
mostly of men. Little data exist with respect to PAD in women. The goal of this review is to highlight what is known
about gender-related differences for PAD. (J Vasc Surg 2013;57:18S-26S.)Peripheral arterial disease (PAD) is a considerable
public health burden because it impairs quality of life
and leads to high rates of morbidity and mortality. It
currently affects between 5 and 10 million Americans,
with the expectation that these numbers will greatly
increase as the population ages and becomes more obese
and more likely to suffer from diabetes. At the time patients
are diagnosed with PAD, >50% present with asymptomatic
disease or complain of atypical leg pain. A smaller
percentage of patients who have PAD also have inter-
mittent claudication distinguished by cramping pain,
discomfort, or a sensation of weakness in the legs that
occurs with exertion and is relieved by rest. Although
claudication symptoms remain stable in 70% to 80% of
patients, approximately 10% to 20% worsen and 1% to 2%
of patients will progress to critical limb ischemia (CLI)
over a 10-year period.1
Some patients experiencing amputations because of
CLI have not had PAD symptoms 6 months before being
diagnosed with CLI. Thus, it is now believed that PAD
does necessarily advance through the traditional stages of
the classiﬁcation schemes. In addition to the functional
impairment, PAD is a strong marker for cardiovascular
events. Patients with PAD have a ﬁvefold to sixfold
increased risk of death or morbidity from other atheroscle-
rotic disease processes such as stroke or coronary artery
disease (CAD).2 Interestingly, although the risk of death
is higher in those with PAD vs without, it is similar in
both asymptomatic and symptomatic patients.3
Caucasian men historically develop PAD. Although
former studies detail a lower frequency of PAD in women,
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://dx.doi.org/10.1016/j.jvs.2012.10.115equal to and perhaps greater than in men. PAD is generally
underdiagnosed, but gender bias may result in a reduction
of screening and management of predisposing risk factors
for women. Differences between the sexes in the time it
takes to diagnose PAD may also contribute to the worse
outcomes observed after treatment for women. Hence,
the intent of this review is to provide an update on
gender-based variations in PAD and show how these differ-
ences may inﬂuence PAD-related outcomes in women.4
PREVALENCE OF PAD IN WOMEN
The American Heart Association estimates that PAD
affects w8 million Americans aged >40 years.5 Further-
more, it is widely recognized that the prevalence of PAD
increases with age; in patients aged <60 years, the preva-
lence is w3%, but in patients aged >70, the prevalence
can approach 15% to 20%.6,7 The American College of
Cardiology (ACC)/American Heart Association (AHA)
2005 practice guidelines for the management of patients
with PAD maintain male sex as a PAD risk factor; however,
these data were from 1985.1 More recent studies have
reported conﬂicting results, with the prevalence of PAD in
women being similar or higher than that of men.8-11 Popu-
lation studies yielded a prevalence of PAD of 16.5% and
19.2% in men and women, respectively, which was not
statistically different.8 However, there was a signiﬁcant
sex-based presentation for asymptomatic PAD,with a higher
prevalence among women than in men (13% vs 9%;
P < .03). Several factors may exist in these studies that
contribute to sex-based differences in prevalence.
Selection bias may contribute to whether the disparities
between genders are mirrored in the groups of patients.
A study from Vogt et al12 showed that in women aged
>60 years with PAD, 6.5% refused ankle blood pressure
and were thereby excluded from the study. Along similar
lines, data were omitted for nearly 20% of the participants
in the National Health and Nutrition Examination Survey
(NHANES) study. Among these individuals, there were
more women and the patients were older.13 Although
the investigators for NHANES did not provide an explana-
tion for this discovery, some have suggested that women
with the diagnosis of PAD may suffer from more functional
impairment from their disease, leading them to stay at
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enroll in a clinical research study.
Skewed data may also be caused by oversampling of
subjects in certain demographic groups. Because the
occurrence of PAD escalates with age, most research tends
to concentrate on older patients, generally those aged
>50 years. Yet, PAD frequency among women may differ
within elderly age groups. As such, a study of demographic
data from PAD patients evaluated at a vascular laboratory
revealed that women were 3.3 years older than men
and made up a larger percentage of the patients aged
>65 years (69% women vs 57% men).14 Other studies,
while reporting a greater frequency of patients with PAD
at age $65 years, have reported a higher prevalence of
PAD among women.8,15 Diehm et al9 noted in their study
that men (19.8%) had a higher incidence of PAD than
women (16.8%). However, for women, the prevalence of
PAD increased with age more than it did with men. In
patients aged <70 years, the occurrence of PAD was 12%
for women and 17% for men. Interestingly, for patients
aged >85 years, women had a higher prevalence of PAD
(39%) than men (27%).9
It is possible that the prevalence of PAD in men may
be due to a bias in screening and diagnosis. Results of
a survey recently conducted of Texan female veterans
found that women are not as likely to talk about a diagnosis
of PAD with doctors.16 Even though 47% of the respon-
dents were at high risk for cardiovascular disease (CVD),
two-thirds reported not discussing vascular-related issues
or disease with their doctor. Women are also reported to
be disproportionately under-represented in randomized
controlled trials for vascular disease.17 Speciﬁcally, for trials
on lower extremity revascularization, women represented
22.4% of study participants, yet the Nationwide Inpatient
Sample data showed that women actually represented
41.3% of this population, indicating that randomized
controlled trials on lower extremity revascularization
under-represented women by w50%. Thus, under-
representation of women and under-reporting of symp-
toms from women contribute to the conﬂicting data on
prevalence of PAD in women.
RISK FACTORS FOR PAD AMONG WOMEN
The risk factors for PAD and CAD are comparable
and include smoking, age, diabetes mellitus, hypertension,
and dyslipidemia.5 Among these risk factors, diabetes and
smoking are associated with the highest odds ratios for
developing PAD (3.0 and 4.0, respectively).5 Although
risk factors such as diabetes mellitus, hypertension, hyper-
lipidemia, and tobacco use are more frequent in African
American populations than in Caucasian populations, these
risk factors have been mostly reported to be similar for
men and women, with a few exceptions. Vouyouka
et al18 found that among >370,000 inpatient surgical
hospitalizations for PAD, women were more likely to be
older, obese, and black. Others have shown that women
presenting with PAD tend to be older and have
dyslipidemias.15,19Supporting the role for obesity amongwomenwithPAD,
Lu et al20 found that among women, a positive relationship
existed between the waist-to-thigh ratio and the waist
circumference and PAD. Urine and blood levels of cadmium
were associated with PAD in men and women, but the
odds ratio for women was signiﬁcantly lower than for men.21
Lastly, as an independent association between hypo-
thyroidism and CAD has been demonstrated, Mazzefﬁ
et al22 investigated whether hypothyroidism is associated
with PAD as well. They found a gender effect that it is
positively associated in men but negatively in women.22
Although it is unknown why some of these gender-based
differences in risk factors may exist, it has been reported
that gender-based differences exist for the management
of these risk factors.
The Reduction of Atherothrombosis for Continued
Health (REACH) registry recruited >68,000 outpatients
aged >45 years.23 Unfortunately, risk factor control was
much less frequent for patients with the diagnosis of
PAD than for patients with a diagnosis of CAD. This
included the management of blood pressure, glycemia,
total cholesterol, and smoking cessation. Upon further
evaluation, men were found to be nearly twice as likely
than women to have optimal risk factor control. Similarly,
an observational population-based study of patients with
PAD from Quebec found that more men than women
were treated with statins, angiotensin-converting enzyme
(ACE) inhibitors, and antiplatelet agents.24 Lastly, a study
by Klein-Weigal et al25 evaluated risk factor management
among medical physicians vs vascular surgeons and found
that medical doctors treated more women than men
compared with vascular surgeons. Medical doctors were
also more likely to document smoking and diabetes and
prescribe statins than vascular surgeons. Thus, gender-
based disparities with risk factor modiﬁcation in patients
with PAD exist and could ultimately affect the progression
of PAD in women, especially as the women age.
Patients who smoke increase the odds of developing
symptomatic PAD by fourfold compared to nonsmokers.26
Cigarette smoking remains the most important risk factor
for the development of PAD. The probability of PAD
multiplies with the amount of smoking exposure and
may be stopped by smoking cessation.11 He et al11 con-
ducted a study in China and discovered that smokers
who quit smoking #10 years had a sustained risk of
developing PAD. The risk was minimal if the patient quit
for >10 years.11
According to the Centers for Disease Control, the prev-
alence of cigarette smoking from 2003 to 2007 in Ameri-
cans was w20%, a relatively stable number over time.
The frequency of women who smoke is between 17% and
19%, which is below average.27 Interestingly, women
with a diagnosis of PAD are more apt to have smoked or
are current smokers than women without PAD. However,
some reports show a lower prevalence of tobacco use
among women with PAD than among men.28-30
There is a connection between the development of
PAD and C-reactive protein (CRP) levels.31 Elevated levels
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recently reported that an increase in D-dimer and CRP,
both inﬂammatory markers, was predictive of 1-year
all-cause and cardiovascular mortality. The Multiethnic
Study of Atherosclerosis (MESA) results showed women
had higher levels of CRP than men, even after adjustment
for comorbidities, hormone status, and age. Decedents
were more likely to be male in the report by Vidula
et al.33 Finally, the speciﬁc role of inﬂammatory markers
has yet to be established in the diagnosis or management
of PAD patients.
With respect to other coexisting conditions that may
affect the risk for developing PAD, such as diabetes mellitus
or hypertension, data suggest that the risk is similar
between the sexes. However, some evidence suggests
that CVD not related to PAD is less prevalent in women
than in men.34 The PAD Awareness, Risk and Treatment:
New Resources for Survival (PARTNERS) study, enrolled
6979 patients aged >50 and <70 years old with a medical
history of tobacco use or diabetes mellitus to ascertain the
relationship between CVD and PAD. Within this group of
patients, 53% had a past medical history of CVD or PAD.
Of the PAD-only group, 61% were women compared
with 44% of the PAD and CVD group.2 Because patients
with PAD and CVD typically receive more aggressive
management of risk factors, such as hyperlipidemia and
hypertension, than patients with only PAD,2 a diminished
identiﬁcation of PAD in female patients may result in less
risk factor modiﬁcation. Patients with PAD from both sexes
possess an overall higher risk of CVD-associated morbidity
and mortality.35
Estrogen and other sex hormones have vasoprotective
properties that lower the prevalence of atherosclerosis in
women of a younger age, yet estrogen is a risk factor for
the development of CVD in women of an older age. After
menopause, therapy with estrogen can cause adverse
changes, such as increased triglycerides and low-density
lipoproteins and a concurrently decreased high-density
lipoprotein in the lipid proﬁle.36 Women have also been
found to have a better vasodilation response to nitric oxide
compared with men, but this diminishes after meno-
pause.37 Premenopausal women have also been found to
have signiﬁcantly more circulating endothelial progenitor
cells than age-matched men and menopausal women.38
The mechanism that accounts for these differences in
premenopausal women is thought to be secondary to the
actions of estrogen. Mendelsohn et al39 demonstrated
that the estrogen-estrogen receptor (ER) complex can
increase the protein expression of endothelial nitric oxide
synthase (eNOS), the enzyme that synthesizes NO in
endothelial cells. Because one of the main cardioprotective
molecules is NO, this may be one mechanism by which
estrogen lowers the risk of developing CVD.
Observational studies have suggested that hormone
replacement therapy (HRT) over the long term may be
beneﬁcial, even though cardiovascular event risk may be
higher over the short term. The Rotterdam study consisted
of 2196 women (aged 55-80 years). Women who usedHRT for >1 year had a 52% decreased risk of PAD. The
risk of developing PAD was not affected with HRT use
for #1 year.40 However, larger well-designed trials like
the Heart and Estrogen/Progestin Replacement (HERS)
and Women’s Health Initiative (WHI) have not demon-
strated a beneﬁt from using HRT with respect to PAD or
CVD.41-43 Two WHI trials: estrogen alone and the
estrogen plus progestin trial revealed more events related
to PAD or reinterventions related to PAD at early time
points.44,45 Neither study, however, discovered an increase
in PAD incidence in those taking HRT, and the HERS
trial reported no change in the rate of events related to
peripheral vascular disease.42,44-46
In summary, the use of inﬂammatory markers, such as
CRP, to diagnose or manage PAD is still investigational.
The prevalence of diabetes mellitus, hypertension, hyper-
lipidemia, and tobacco use remain similar in men and
women who have PAD. However, because women more
often present with asymptomatic PAD and are less often
diagnosed with CVD risk factors, they may not receive
the same risk factor modiﬁcation therapy as men. Lastly,
HRT does not appear to reduce the odds of developing
PAD in postmenopausal women and may even increase
the risk of morbidity from vascular interventions.
PRESENTATION OF PAD AMONG WOMEN
Variability exists in the presentation of PAD. Symp-
toms of PAD are classiﬁed according to the Fontaine or
Rutherford classiﬁcations, but patients do not always
present as a logical progression through these classiﬁcations
or stages. In accordance with the 2005 ACC/AHA prac-
tice guidelines for the management of patients with PAD,
intermittent claudication will manifest in <10% of patients
with PAD1,2 Approximately 50% of patients with PAD will
manifest atypical symptoms of pain, and the remainder of
patients (40%) will be asymptomatic. Most studies have
shown that asymptomatic disease is more prevalent in
women than in men.2,15,47
Furthermore, an interview-based study at the Univer-
sity of Minnesota found subtle differences in how men
and women described their symptoms of claudication,
with twice as many women as men describing their symp-
toms with pathophysiologic descriptions.48 However,
studies have suggested that variation exists among women,
in the frequency of different symptoms. McDermott et al47
reported that in a study of disabled elderly women,
63% presented with no complaints of leg pain. A study of
Swedish patients reported that a larger percentage of
women presented with intermittent claudication vs
American and Dutch groups, although women (12.9%)
with the diagnosis of PAD were more prone than men
(9.4%) to present with no leg pain symptoms (P ¼ .03).8
Activity level is possibly related to the higher occur-
rence of asymptomatic disease in women. Recently,
McDermott et al49 reported a linear relationship between
disease severity and the presence of exertional leg symp-
toms in asymptomatic women with PAD, but only among
patients who walked >4 blocks per week. This linear
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walked <4 blocks per week.49 Also, women may present
with unusual signs that are ascribed to other comorbidities,
such as spinal stenosis. Because a substantial number of
patients are diagnosed by primary care providers who
draw on patient history more often than noninvasive
vascular testing of the ankle-brachial index (ABI), the
patient’s activity level should be ascertained during
screening for those patients who are suspected to have
PAD; this will help establish whether a lack of symptoms
is an indicator of the presence of disease.
An increase in asymptomatic disease, associated with
a decrease in recognition and later intervention, may
produce a higher percentage of women who present
with CLI and severe disease than men. A study from
Northwestern University reported that when patients
were sent to the vascular laboratory for evaluation of sus-
pected PAD, women were more likely than men to be
diagnosed with severe disease based on the ABI.14 A study
from Italy demonstrated a similar ﬁnding, that women
who were sent to the vascular laboratory for evaluation
of PAD more often presented with symptoms of CLI
than men (13% vs 4%).15
Treatment of patients with CLI requires substantial
resources, because CLI eventually necessitates interven-
tion; fortunately, this represents a small proportion of all
patients who have PAD. In addition, a signiﬁcant problem
associated with the delay in presentation or presentation
with more severe disease in women is that this may account
for why women undergo fewer revascularization proce-
dures and more amputations than men (see below).
When compared with men, data suggest that women
more often present with advanced disease, have a poorer
quality of life, and baseline lower extremity function. In
a 403-patient study by Collins et al,16 women were more
likely to have impaired walking scores compared with
men with PAD and women without PAD. Furthermore,
physical function and general health scores were lower
for women with PAD than men with PAD.16 Comparable
results were reported in a study by McDermott et al.50 In
a group of 273 men and women with PAD, women had
lower walking speeds, shorter 6-minute walking distances,
and lower performance scores, even after adjusting for
comorbidities and leg symptoms.50 The authors proposed
that a correlation between lower extremity impairment
and leg strength may exist and that leg exercises to
strengthen the legs may be helpful for patients with PAD.
Most recently, Gardner et al51 showed that women
with intermittent claudication ambulated slower than
men in a community setting. Speciﬁcally, they found that
women had a lower adjusted daily maximal cadence for
5 minutes of ambulation, 1 minute of ambulation, and
for intermittent ambulation. These changes in women
correlated with changes in their calf muscle oxygen satura-
tion during exercise. Thus, although women who have
PAD may have worse function of the lower extremities
than men, the question remains whether this decreased
lower extremity function can prognosticate outcomes.Although research has failed to demonstrate that
diminished function of the lower extremities in individuals
diagnosed with PAD is related to adverse clinical outcomes,
data appear to suggest that a relationship exists between
function and quality of life in individuals diagnosed with
PAD. A decrease in quality of life among patients diag-
nosed with PAD has been reported with women who carry
the diagnosis of PAD compared with men, when functional
status is controlled for.52 A study from the University of
California at Los Angeles found that among patients with
PAD, after controlling for disease severity, women
described more physical dysfunction, pain, and mood
disturbances than men, leading to lower overall quality of
life. The authors ascribe these ﬁnding to sex-based differ-
ences because the results were established despite disease
severity, comparable age, and an increased occurrence of
associated comorbidities in the men, which can negatively
affect quality of life.52 The decreased quality of life may
be related to depression.
Smolderen et al53 reported that women with newly
diagnosed PAD experienced a fourfold greater odds of
baseline depression as well as development of subsequent
depressive symptoms than men aged $65 years. Because
worse outcomes after revascularization of an affected limb
have been associated with depression, these data may
have real clinical importance.54
Exercise may enhance quality of life in patients with
diminished function of the lower extremity in the setting
of PAD. In addition, exercise is known to reduce overall
cardiovascular risk for death. McDermott et al55 recently
conducted a randomized controlled trial that found that
treadmill exercise and resistance training in patients with
PAD, with and without symptoms, improved walking
performance, stair climbing, and quality of life. However,
no gender analysis was performed for this study.DIAGNOSIS OF PAD
Most patients with PAD are asymptomatic, although
the use of screening questionnaires for the presence of
symptoms can help to discover PAD. Physical examination
can be informative, especially the ﬁndings of carotid or
other bruits, differential blood pressure measurements,
and diminished or absent peripheral pulses. Use of more
noninvasive testing that is objective is necessary if patients
are at high risk for developing PAD. The World Health
Organization/Rose Claudication questionnaire can be
used. However, although it has been found to have
a high speciﬁcity for the detection of PAD, it has a low
sensitivity.6 Several studies maintain that using only symp-
toms to diagnose PAD can result in a high proportion of
false-negative results.9,11 He et al11 conducted a study of
Chinese patients for which PAD prevalence was 12%
when diagnosed by the Rose Questionnaire but 16%
when an ABI <0.9 was used. Prevalence was increased to
20.7% when using a combination of the two methods.11
Therefore, although patient history and physical examina-
tion are helpful for the general diagnosis of PAD and to
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when forming a deﬁnitive diagnosis.
The ABI is the standard screening study for the diag-
nosis of PAD. The Inter-society Consensus for the
Management of PAD (TASC II) document details the
standard measure of ABI.56 An ABI <0.9 indicates the
patient has PAD. Used in combination with segmental
plethysmography or pulse volume recordings (PVRs)
increased the accuracy to 95%.7 However, the ABI is not
without challenges, because it can be falsely elevated to
values >1.4 in patients with PAD but noncompressible
calciﬁed arteries, often observed in patients with diabetes
mellitus. Most studies usually exclude patients with ABI
elevated >1.3 to 1.4. A review of ABIs performed as part
of the PARTNERS program showed that male sex was
positively associated with a high ABI.57 Furthermore, those
with a high ABI were shown to be at an increased risk for
foot ulcers and neuropathy.
Exercise testing using heel raises or a treadmill and
measurement of the ABI may improve the sensitivity for
patients with exertional leg symptoms and a normal resting
ABI.58 In a 396-patient study of patients who were referred
to a vascular laboratory for rest pain, intermittent claudi-
cation, and ulceration, the ABI was <0.9 in 31%, and
46.2% of the patients had an ABI >0.9 at rest. After
a 5-minute walk on a treadmill set with a 12% incline at
2.0 miles/h, the ABI fell <0.9 in 31%, which conﬁrmed
the diagnosis of PAD.59
For the ABI, 0.9 is typically the cutoff for the diagnosis
of PAD, with values <0.9 indicating the presence of PAD.
Although different ABI thresholds for the diagnosis of
PAD are not standard, some research has suggested that
the limit should be different between the sexes. The Multi-
ethnic Study of Atherosclerosis used an ABI limit of 0.88 to
reevaluate the PAD prevalence in women. The prevalence
of PAD in women dropped from 3.5% to 2.2% and the
ratio for women to men inverted from 1.3 to 0.8. Thus,
the authors suggested that the use of an ABI of 0.9 to indi-
cate PAD may overestimate PAD prevalence by 37% in
non-Hispanic Caucasian women and by 36% in black
women.60 Use of a lower ABI limit in women has been
suggested to be necessary due to smaller-sized arteries in
women61 or to the relationship between ABI and height.
Results of the Atherosclerosis Risk in Communities
(ARIC) study found differences in the average ABI
between men and women, but after adjusting the ABI
values for height, the differences were eliminated.62 Never-
theless, given that the standard error from measurement to
measurement with the ABI isw0.15, these differences may
not be great. Thus, most physicians use an ABI <0.9 to
diagnose PAD, regardless of the patient’s sex.1
The reason for using the ABI as a criterion is because
the ABI has been shown to be related to PAD severity.
For instance, patients with ABIs of <0.5 have been found
to have a greater risk for CLI, and ABIs of <0.4 are
associated with rest pain or tissue loss, or both.1 Increased
mortality is associated with a lower ABI. A recent study of
1101 patients from the Prevalence of PAD in Patients withAcute Coronary Syndrome registry showed that patients
with an ABI of <0.9 and acute coronary syndrome were
more likely to have other cardiovascular risk factors, such
as diabetes mellitus and stroke. These patients also had
a greater risk of death and were more likely to develop
heart failure than patients with an ABI of >0.9.63
The Ankle Brachial Index Collaboration group con-
ducted an epidemiologic review to determine if the ABI
would improve the cardiovascular risk assessment of the
Framingham risk score (FRS). Interestingly, the study
reported a higher 10-year risk of death for both men and
women when using the ABI and even after adjusting for
the FRS. The effect was most dramatic for women.64
Thus, the authors concluded that incorporation of the
ABI into cardiovascular risk stratiﬁcation assessment may
improve the accuracy of the prediction and lead to better
risk factor modiﬁcation.
Duplex ultrasound imaging is a safe and effective
method of determining the presence and location of
stenoses and occlusions in the periphery without radiation.
B-mode imaging provides a two-dimensional image of the
artery wall and displays plaque characteristics, which may
be important in determining risk. Color-ﬂow Doppler
and pulsed-wave Doppler evaluations deﬁne the degree
of stenosis according to velocity measurements.65 Because
the test is inexpensive and risk-free, ultrasound imaging has
great utility as a means of identifying subclinical atheroscle-
rosis before the development of symptoms. Ultrasound
screening of carotid and femoral arteries in a population
with low or intermediate FRS was undertaken to determine
whether patients who would beneﬁt from intensive risk
modiﬁcation could be identiﬁed. Unlike men, in whom
the presence or absence of risk factors did not predict the
frequency of ﬁnding plaque, only a small number of
women without risk factors and aged <50 years demon-
strated the presence of plaque. This indicates that screening
for PAD in this group provides little advantage.19
Other imaging, such as magnetic resonance imaging
(MRI) or computed tomography (CT), is normally ob-
tained for patients with a PAD diagnosis to more precisely
determine the location of disease and determine if the
anatomy is amenable to revascularization. The gold standard
for the diagnosis of PAD remains contrast angiography;
however, this evaluation modality is invasive and associated
with risks, including contrast-induced nephropathy, local
injury to the artery, and radiation exposure. MR angiog-
raphy (MRA) is not used for ﬁrst-line screening because it
is costly, time-consuming, and exposes the patient to risks,
such as contrast-induced nephropathy and anxiety, for
patients who are claustrophobic. MRA also requires special
software for postimaging processing and knowledge of
how to use this software. However, MRA does have a sensi-
tivity of 90% to 94% and a speciﬁcity of 90% to 94% for the
diagnosis of PAD.2
TREATMENT AND OUTCOMES
The treatment goals in patients with PAD have two
intents: decrease cardiovascular morbidity and mortality
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quality of life. These goals are achieved by a combination
of reduction of risk factors, medical treatment of claudica-
tion, and revascularization when indicated. Smoking cessa-
tion is imperative. Treatment of coexisting medical disease,
such as diabetes mellitus, hyperlipidemia, and hyperten-
sion, has been reported to reduce morbidity and mortality
in patients diagnosed with PAD.36 An example is the use of
ACE inhibitors for hypertension. ACE inhibitors have been
reported to lower the risk of cardiovascular events in PAD
patients.66 Statin use may improve walking distance and
speed in claudicants as well as slow progression of disease.67
In the HERS trial, statin use in women decreased the risk
of CAD and myocardial infarction and appeared to abro-
gate some of the detrimental effects of HRT.68
The research on the effect of antiplatelet agents on the
progression of PAD is not as clear. The Clopidogrel vs
Aspirin in Patients at Risk of Ischemic Events (CAPRIE)
study in 1996 enrolled nearly 20,000 patients, including
6,452 who were diagnosed with PAD. Patients were
randomized to receive clopidogrel or aspirin for w2 years.
Clopidogrel reduced the risk of myocardial infarction,
stroke, or vascular death for patients with symptomatic
PAD by 24% compared the cohort that received aspirin.69
More recently, a meta-analysis was performed of random-
ized controlled trials using aspirin in patients diagnosed
with PAD. This study found that the risk of nonfatal stroke
was reduced by aspirin alone or in combination with
dipyridamole, but the risk of cardiovascular events, nonfatal
myocardial infarction, cardiovascularmortality, and all-cause
mortality was not reduced.70
TASC II recommended the use of antiplatelet therapy,
particularly aspirin, for patients with PAD; however, the
data only conclusively supported use in patients with cere-
brovascular disease or CAD.56 No recommendations were
made based on sex in the TASC II document for patients
with PAD.
Research has also found that PAD patients with
a concomitant diagnosis of CAD are more prone to be
treated with an antiplatelet drug, ACE inhibitor, or statin
than those who do not have a concomitant diagnosis of
CAD.71 In the American Vascular Association Screening
Program, of the 2,446 people enrolled, PAD was diag-
nosed in 9%. Of those patients with PAD, only 47% were
found to be receiving statins or antiplatelet agents, and
more men (58%) were receiving antiplatelet agents than
women (40%). A similar pattern was observed for statin
use, with 87% of the men and 63% of the women reporting
use.71
Sigvant et al34 recently conducted a study in Sweden
and reported a similar pattern. Women diagnosed with
PAD were less likely to seek pharmacologic treatment
for risk factor reduction. When compared with women,
the odds ratio for men receiving pharmacologic therapy
was 1.3 for b-blockers or ACE inhibitors, 1.3 for lipid-
lowering therapy, and 1.6 for antiplatelet therapy.34 These
ﬁndings are similar to a study undertaken in Canada evalu-
ating differences in the use of antiplatelet agents, statins,and ACE inhibitors between men and women. Although
antiplatelet therapy was similar for men and women, men
were much more likely to receive all three treatments
(22.4% vs 18.2%; P < .005), and more women than men
used only one agent (33.4% vs 30.0%).24
A program of supervised exercise is recommended
for patients with intermittent claudication. Research has
established that following a regular exercise regimen can
improve the total distance PAD patients can walk.72 Two
medications, pentoxifylline and cilostazol, have been
approved by the U.S. Food and Drug Administration for
use in claudication. The response to pentoxifylline is small.
Cilostazol, a phosphodiesterase III inhibitor, has improved
peak treadmill performance and quality of life in multiple
randomized trials.73 Revascularization may be indicated
for patients who have more advanced disease or progres-
sion of symptoms.
Clear indications for revascularization include ischemic
rest pain, ischemic ulceration, gangrene, or symptomatic
disabling claudication. The decision to pursue or not
pursue revascularization in women may be inﬂuenced by
their higher rate of asymptomatic presentation. A study
from Northwestern University reported that men were
more likely to undergo an intervention for their PAD
than women, even when considering only patients with
CLI. Men were also more likely to be selected for inter-
vention than women, even after controlling for potential
confounding factors.14 Fortunately, a recent reassessment
of patients evaluated in the vascular laboratory at this
same institution was just conducted (15 years after the ﬁrst
publication). These data indicate that this gender bias has
been rectiﬁed since the earlier study, possibly because of
increased awareness of the original data.74
Women are usually older compared with men and have
worse disease when they have lower extremity revasculari-
zation. Procedural outcomes for women could be nega-
tively affected because of these factors.75,76 In a study of
patients from Albany, of 5,880 procedures, 13% of men
but only 8% of women underwent interventions for
intermittent claudication. However, 90% of women vs
81% of men underwent intervention for limb salvage.75
Evaluating procedural outcomes, this study indicated that
graft patency was the same between men and women.
Ahchong et al77 analyzed 211 infrainguinal bypass proce-
dures in China and reported contrasting results: women
had worse 3-year graft patency results (33%) than men
(49%). They postulated that this was secondary to the
fact that women had smaller infrapopliteal arteries and
vein conduits than men (2.0 vs 2.5 mm; P ¼ .03).77 These
ﬁndings were supported by an analysis of the clinical data-
base Project of Ex Vivo Vein Graft Engineering via Trans-
fection III (PREVENT III) database in which women had
more adverse events, including graft failure and limb loss,
after vascular bypass grafting compared with men.78
Hormone replacement therapy in postmenopausal
women has been associated with worse outcomes after
lower extremity revascularization in women. Timaran
et al79 analyzed outcomes of women after iliac angioplasty
JOURNAL OF VASCULAR SURGERY
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primary patency rates when using HRT (HRT 49% vs
non-HRT 74%; P ¼ .02).79 A different study from the
same institution observed that HRT had a similar effect
on patency in women after femoropopliteal bypass graft-
ing.80 As noted by the HERS study, patients receiving
HRT are at an increased risk for developing venous throm-
boembolic events.46 The conclusions from this study may
help to clarify the increased risk of peripheral arterial events
observed in the WHI studies.44,45 From these studies,
authors have suggested that women with PAD taking
HRT should consider discontinuing the HRT 4 to 6 weeks
before a vascular intervention.36,46
Although a high rate of postoperative wound compli-
cations in women after revascularization was noted in
some sex-based outcomes studies, there was no signiﬁcant
difference in mortality between men and women.75,81 The
PREVENT study, which included 1400 patients who
received lower extremity revascularization for CLI, re-
ported a 39% wound complication rate by 30 days.81
Female gender and oral anticoagulation were the only vari-
ables that independently predicted wound complications,
with an odds ratio of 1.4. Although wound complications
were associated with more deaths and limb loss, they
were not associated with graft patency. Other investigators
have proposed that women with diabetes are at greater risk
for complications than men with diabetes.82,83 Nguyen
et al81 suggested that hormonal factors, and the amount
and distribution of body fat, may be factors in the
increased risk for women; however, these variables were
not quantiﬁed.
Vouyouka et al18 did ﬁnd a higher postoperative
mortality in women of 5.26% vs 4.21% in men (P <
.0001). In addition, all types of vascular surgery, including
endovascular and open revascularizations and major ampu-
tation, were statistically more likely to be complicated by
bleeding in women, with an odds ratio of 1.33. A higher
rate of periprocedural infection was observed after open
revascularizations, a combination of open and endovascular
procedures, and major amputations. No difference in infec-
tion rates between men and women were found after
strictly endovascular procedures, but the overall infection
rate for these interventions is low.
CONCLUSIONS
Female sex has an important effect on the diagnosis
and treatment of PAD. Women with PAD are more likely
to present without symptoms. As a consequence, their
vascular disease has been underdiagnosed and under-
treated. As the population ages, the prevalence of PAD
will increase signiﬁcantly. Among the elderly, there are
more women than men, with the disparity being greatest
in the oldest age groups; consequently, morbidity and
mortality from PAD will become increasingly common
for women. There has been an increased effort to delin-
eate the effects of sex on the clinical burden and risks pre-
sented by PAD. Better knowledge of these effects will
hopefully result in the development of strategies to achievesex-speciﬁc cardiovascular risk reduction and improvement
in overall quality of life for women.
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